Nanomedicine: de novo design of nanodrugs

Nanoscale. 2014 Jan 21;6(2):663-77. doi: 10.1039/c3nr04535h.

Abstract

Phenomenal advances in nanotechnology and nanoscience have been accompanied by exciting progress in de novo design of nanomedicines. Nanoparticles with their large space of structural amenability and excellent mechanical and electrical properties have become ideal candidates for high efficacy nanomedicines in both diagnostics and therapeutics. The therapeutic nanomedicines can be further categorized into nanocarriers for conventional drugs and nanodrugs with direct curing of target diseases. Here we review some of the recent advances in de novo design of nanodrugs, with an emphasis on the molecular level understanding of their interactions with biological systems including key proteins and cell membranes. We also include some of the latest advances in the development of nanocarriers with both passive and active targeting for completeness. These studies may shed light on a better understanding of the molecular mechanisms behind these nanodrugs, and also provide new insights and direction for the future design of nanomedicines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry
  • Drug Carriers / chemistry
  • Escherichia coli / drug effects
  • Humans
  • Nanomedicine*
  • Nanoparticles / chemistry
  • Neoplasms / diagnosis
  • Neoplasms / drug therapy

Substances

  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Drug Carriers